Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent.[2] Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth.[2][4]
The most common side effects include tiredness or weakness, nausea (feeling sick), increased levels of creatinine (which may indicate kidney problems) and liver enzymes in the blood (which may indicate liver damage), vomiting, anaemia (low red blood cell counts), decreased appetite, dysgeusia (taste disturbances), diarrhoea, thrombocytopenia (low levels of platelets) and abdominal pain (belly ache).[3][2]
^"Rubraca 200mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 19 June 2019. Archived from the original on 29 August 2021. Retrieved 17 May 2020.
^ abcde"Rubraca- rucaparib tablet, film coated". DailyMed. 6 April 2018. Archived from the original on 9 May 2020. Retrieved 17 May 2020.
^ abCite error: The named reference Rubraca EPAR was invoked but never defined (see the help page).
^"Cancer Research Launches New Drug Trial". netdoctor.co.uk. Hearst Magazines UK. 10 January 2012. Archived from the original on 26 December 2017. Retrieved 20 December 2016.
Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting...
claims it exaggerated to investors the efficacy of Roci in patient trials. Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian...
who have been treated with three or more prior lines of chemotherapy. Rucaparib: On December 19, 2016, the US FDA granted accelerated approval for previously...
glioblastoma, discovered by CRUK scientists at the University of Aston. Rucaparib, a PARP inhibitor drug discovered by CRUK scientists including Ruth Plummer...
Translational Cancer Research Prize from Cancer Research UK for work using rucaparib to treat ovarian cancer. Plummer was elected as a fellow of the UK's Academy...
navitoclax, and gossypol. PARP inhibitors (e.g. FDA approved olaparib, rucaparib, niraparib and talazoparib) PI3K inhibitors (e.g. perifosine in a phase...
which biomarkers are predictive of responsiveness to PARP inhibitors. Rucaparib is another PARP inhibitor being researched in BRCA-positive and BRCA-negative...
checkpoint inhibitor drug pembrolizumab and PARP inhibitors, namely olaparib, rucaparib, or niraparib. Bone metastases – present in around 85% of those with metastatic...
Global Information
